52
Views
27
CrossRef citations to date
0
Altmetric
Research Article

Comparison of Indomethacin and Nimesulide, a Selective Cyclooxygenase-2 Inhibitor, on Key Pathophysiologic Steps in the Pathogenesis of Nonsteroidal Anti-Inflammatory Drug Enteropathy in the Rat

Pages 728-735 | Published online: 08 Jul 2009

References

  • Barrier CH, Hirschowitz BI. Current controversies in rheumatology. Controversies and management of non-steroidal antiinflammatory drug induced side effects on upper gastrointestinal tract. Arthritis Rheum 1989; 32: 926–9.
  • Bjarnason I, Hayllar J, Macpherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 1993; 104: 1832–47.
  • Somasundaram S, Hayllar J, Rafi S, Wrigglesworth J, Macpherson A, Bjarnason I. The biochemical basis of NSAID-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995; 30: 289–99.
  • Wallace JL, Granger DN. Pathogenesis of NSAID gastropathy: are neutrophils the culprits? Trends Pharmacol Sci 1992; 13: 129–30.
  • Whittle BJR. Unwanted effects of aspirin and related agents on the gastrointestinal tract. In: Vane JR, Botting RM, editors. Aspirin and other salicylates. London: Chapman & Hall Medical; 1992. p. 465–509.
  • Wallace JL. Nonsteroidal anti-inflammatory drugs and gastro-enteropathy: the second hundred years. Gastroenterology 1997; 112: 1000–16.
  • Mahmud T, Rafi SS, Scott DL, Wrigglesworth JM, Bjarnason I. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arth Rheum 1996; 39: 1998–2003.
  • Somasundaram S, Rafi S, Jacob M, Sigthorsson G, Mahmud T, Sherwood R, et al. Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Gut 1997; 40: 608–13.
  • Anthony A, Trasivoulou C, Dhillon AP, Pounder RE, Wakefield AJ. Pre-ulcerative villous contraction and microvascular occlusion induced by indomethacin in the rat jejunum. Aliment Pharmacol Ther 1995; 9: 605–13.
  • Nygard G, Anthony A, Piasecki C, Trevethick MA, Hudson M, Dhillon AP, et al. Acute indomethacin-induced jejunal injury in the rat: early morphological and biochemical changes. Gastroenterology 1994; 106: 567–75.
  • Vane JR. Towards a better aspirin. Nature 1994; 367: 215–6.
  • Vane JR, Botting RM. Overview—mechanisms of action of anti-inflammatory drugs. In: Vane J, Botting J, Botting R, editors. Improved non-steroidal anti-inflammatory drugs. COX-2 enzyme inhibitors. Dordrecht: Kluwer Academic Publishers; 1996. p. 1–27.
  • Boyce S, Chan CC, Gordon R, Li CS, Rodgers W, Webb JK, et al. L-745,337: a selective inhibitor of cyclooxygenase-2 elicits antinocieption but not gastric ulceration in rats. Neuropharmacology 1994; 33: 1609–11.
  • Churchill L, Graham AG, Shih CK, Pauletti D, Farina PR, Grob PM. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Immunopharmacology 1996; 4: 125–35.
  • Akarasereennont P, Mitchell JA, Theimermann C, Vane J. Relative potency of NSAIDs as inhibitors of Cox-1 or Cox-2. Br J Clin Pharmacol 1994; 112: 183P.
  • Mitchell JA, Akarasereenout P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90: 11693–7.
  • Garavito RM. The three-dimensional structure of cyclooxygenases. In: Vane J, Botting J, Botting R, editors. Improved non-steroid anti-inflammatory drugs. COX-2 enzyme inhibitors. Dordrecht: Kluwer Academic Publishers; 1996. p. 2943.
  • Herbette LG, Vecchiarelli M, Trummlitz G. NSAID mechanism of action: the role of intracellular pharmacokinetics. In: Vane J, Botting J, Botting R. editors. Improved non-steroid antiinflammatory drugs. COX-2 enzyme inhibitors. Dordrecht: Kluwer Academic Publishers; 1996. p. 85–102.
  • Tavares IA, Bishai PM, Bennett A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Drug Res 1995; 45: 1093–5.
  • Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, et al. Mitochondrial damage: a possible mechanism of the ‘topical’ phase of NSAID-induced injury to the rat intestine. Gut 1997; 41: 344–53.
  • Velo GP. The anti-inflammatory, analgesic and antipyretic activity of nimesulide in experimental models. Drug Invest 1991; 3 Suppl 3: 10–3.
  • Tofanetti O, Casciarri I, Cipolla PV, Omini C. Effect of nimesulide on cyclo-oxygenase activity in rat gastric mucosa and inflammatory exudate. Med Sci Res 1989; 17: 745–6.
  • Swingle KF, Moore GGI, Grant TJ. 4-Nitro-2-phenoxymetha-nesulfonanilide (R-805): a chemically novel anti-inflammatory agent. Arch Int Pharmacodyn 1976; 221: 132–9.
  • Schneider WC, Hogeboom KEO. Intracellular distribution of enzymes. V. Further studies on the distribution of cytochrome c in rat liver homogenates. J Biol Chem 1950; 183: 123–8.
  • McLaughlin SGA, Dilger JP. Transport of protons across membranes by weak acids. Physiol Rev 1980; 60: 825–63.
  • Chance B, Williams GR. The respiratory chain and oxidative phosphorylation. Adv Enzymol 1956; 17: 65–134.
  • Tavares IA, Bennett A. Acemetacin and indomethacin: differential inhibition of constitutive and inducible cyclo-oxygenase in human gastric mucosa and leukocytes. Int J Tiss Reac 1993; 15: 49–53.
  • Tavares IA, Collins PO, Bennett A. Inhibition of prostanoid synthesis by human gastric mucosa. Aliment Pharmacol Ther 1987; 1: 617–26.
  • Bjarnason I, Smethurst P, Levi AJ, Peters TJ. Intestinal permeability to 51CrEDTA in rats with experimentally induced enteropathy. Gut 1985; 26: 579–85.
  • Davies NM, Roseth AG, Appleyard CB, Mcknight W, DelSoldato P, Calignano A, et al. NO-naproxen versus naproxen: ulcerogenic, analgesic and anti-inflammatory effect. Aliment Pharmacol Ther 1997; 11: 69–79.
  • Tyler DD. Respiratory enzyme systems of mitochondria. In: The mitochondria in health and disease. New York: VCH Publishers; 1991.
  • Mahmud T, Somasundaram S, Sigthorsson G, Simpson RJ, Rafi S, Foster R, et al. Enantiomers of flurbiprofen can distinguish key pathophysiologic steps of NSAID-enteropathy in the rat. Gut. In press.
  • Picot D, Loll PJ, Garavito RM. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367: 243–9.
  • Xie W, Chipman JG, Robertson DL, Erikson RL, Simmonds DL. Expression of nitrogen-responsive gene encoding synthase is regulated by mRNA splicing. Proc Natl Sci USA 1991; 88: 2692–6.
  • Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegemen RA, Pak JY, et al. Structural basis for selective inhibition of cycoloxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644–8.
  • Davies NM, Wright MR, Russell AS, Jamali F. Effect of the enantiomers of flurbiprofen, ibuprofen, and ketoprofen on intestinal permeability. J Pharm Sci 1996; 85: 1170–3.
  • Brookes PM, Day RO. Nonsteroidal antiinflammatory drugs-differences and similarities. N Engl J Med 1991; 324: 1716–25.
  • Brune K, Schwietzer A, Eckert H. Parietal cells of the stomach trap salicylates during absorption. Biochem Pharmacol 1977; 26: 1735–40.
  • Kargan S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini S, et al. Characterisation of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tract. Gastroenterology 1996; 111: 445–54.
  • Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxidereleasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524–30.
  • Ligumski M, Golanska EM, Hansen DG, Kauffman GL. Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in the rat. Gastroenterology 1983; 84: 756–61.
  • Levine RA, Petokas S, Nandi J, Enthoven D. Effects of nonsteroidal anti-inflammatory drugs on gastrointestinal injury and prostanoid generation in healthy volunteers. Dig Dis Sci 1988; 33: 660–6.
  • Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, et al. Prostaglandin synthase 1 gene disruption in mice reduced arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483–92.
  • Elson CO, Sartor BR, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344–67.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.